Back to Journals » Pharmacogenomics and Personalized Medicine » Volume 14

Genetic Polymorphism Effect on Warfarin–Rifampin Interaction: A Case Report and Review of Literature

Authors Salem M, Eljilany I, El-Bardissy A, Elewa H

Received 27 October 2020

Accepted for publication 29 December 2020

Published 26 January 2021 Volume 2021:14 Pages 149—156


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Martin Bluth

Muhammad Salem,1 Islam Eljilany,2 Ahmed El-Bardissy,1 Hazem Elewa2,3

1Department of Pharmacy, Hamad General Hospital, Doha, Qatar; 2College of Pharmacy, QU Health, Qatar University, Doha, Qatar; 3Biomedical and Pharmaceutical Research Unit, QU Health, Qatar University, Doha, Qatar

Correspondence: Ahmed El-Bardissy
Department of Pharmacy, Hamad General Hospital, PO Box 3050, Doha, Qatar
Tel +974 5523 9167

Abstract: Warfarin–rifampin interaction has been reported since the 1970s. Due to rifampin’s strong induction of CYP2C9, most cases could not attain the target international normalized ratio (INR) despite warfarin dose escalation. Genetic polymorphisms determine up to 50% of warfarin dose variability. A 38-year-old woman was started on warfarin and rifampin for cerebral venous sinus thrombosis and pulmonary tuberculosis. Over six weeks, the daily warfarin dose was increased from 3 to 10 mg to attain three consecutive in-clinic therapeutic INRs. She completed three complications-free months of warfarin treatment with time in therapeutic range (TTR) of 46%. We performed retrospective genetic testing to determine the patient’s CYP2C9, CYP4F2, and VKORC1 genotypes and whether they had affected the interaction outcome. The analysis revealed that the subject carries CYP2C9*3*3 and VKORC1-1639 (GA) mutations, classifying her as a slow metabolizer and, hence, highly warfarin-sensitive. This was reflected on how the case responded to a relatively lower dose than previously reported cases that did not achieve the target on warfarin daily doses up to 35 mg. This is the first report addressing the genotype effect on this interaction. Patients with genetic variants requiring low warfarin doses are more likely to respond at a feasible dose while on rifampin. Future studies to evaluate warfarin–rifampin-gene interaction are warranted.

Keywords: warfarin, rifampin, interaction, CYP2C9, VKORC1, genotype

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under a Creative Commons Attribution License. The full terms of the License are available at The license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Download Article [PDF]  View Full Text [HTML][Machine readable]